David Johnson

David (DJ) Johnson is an accomplished leader in the biopharmaceutical industry, currently serving as Chief Operating Officer at Vera Therapeutics, Inc. since July 2024. Johnson holds a position on the Board of Directors at Caribou Biosciences and is a Business Advisor for Alzheon, Inc. Additionally, Johnson served as Chief Commercial Officer at Global Blood Therapeutics from March 2018 to January 2023 and held multiple senior roles at Gilead Sciences from October 2003 to March 2018, where significant contributions were made to the hepatitis and HIV franchises. Earlier career experience includes serving as Director of Global Commercial Strategy at GlaxoSmithKline Inc. from 1992 to 2003. Johnson earned an Executive MBA from UNC Kenan-Flagler Business School and a BA in Business Marketing and Communications from the University of Puget Sound.